Synergy of L-arginine and growth hormone (GH)-releasing peptide-2 on GH release: influence of gender

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this controlled clinical trial publication.

The researchers test the hypotheses that 1) growth hormone (GH)-releasing peptide-2 (G) synergizes with L-arginine (A), a compound putatively achieving selective somatostatin withdrawal and 2) gender modulates this synergy on GH secretion.

Blood was sampled at 10-min intervals for later chemiluminescence assay of serum GH concentrations.

Who Took Part

According to the abstract, 18 volunteers were involved.

By PubMed's age tags, the people studied were adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized study.

The volunteers were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

What Was Measured

The researchers test the hypotheses that 1) growth hormone (GH)-releasing peptide-2 (G) synergizes with L-arginine (A), a compound putatively achieving selective somatostatin withdrawal and 2) gender modulates this synergy on GH secretion.

The subject headings attached to it are Activity Cycles, Analysis of Variance, Arginine, Half-Life, Hormones, Human Growth Hormone and Luminescent Measurements.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 18 volunteers.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2000 (American journal of physiology. Regulatory, integrative and comparative physiology), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.